Recombinant Human Tumor Necrosis Factor Receptor Superfamily Member 13B Protein (TNFRSF13B), Active

Name: Recombinant Human Tumor Necrosis Factor Receptor Superfamily Member 13B Protein (TNFRSF13B), Active
Brand: Beta LifeScience
SKU: BLC-06043P
Price: 287.2 USD
Availability: InStock

Collections: Cytokines, Cytokines and growth factors, Recombinant proteins, Tumor necrosis factors and receptors (tnfs)

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Tumor Necrosis Factor Receptor Superfamily Member 13B Protein (TNFRSF13B), Active is produced by our E.coli expression system. This is a protein fragment.
Purity	Greater than 95% as determined by SDS-PAGE and HPLC.
Endotoxin	Less than 1.0 EU/μg as determined by LAL method.
Activity	Fully biologically active when compared to standard. The biological activity is determined by its ability to block human BAFF induced T2B cell survival using a concentration range of 1.0-3.0 ug/ml.
Uniprotkb	O14836
Target Symbol	TNFRSF13B
Synonyms	TNFRSF13B; TACI; Tumor necrosis factor receptor superfamily member 13B; Transmembrane activator and CAML interactor; CD antigen CD267
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	Tag-Free
Complete Sequence	MSGLGRSRRG GRSRVDQEER FPQGLWTGVA MRSCPEEQYW DPLLGTCMSC KTICNHQSQR TCAAFCRSLS CRKEQGKFYD HLLRDCISCA SICGQHPKQC AYFCENKLRS PVNLPPELRR QRSGEVENNS DNSGRYQGLE HRGSEASPAL PGLKLSADQV
Expression Range	1-160aa
Protein Length	Partial
Mol. Weight	18.0 kDa
Research Area	Cancer
Form	Lyophilized powder
Buffer	Lyophilized from a 0.2 µm filtered PBS, pH 7.4
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Receptor for TNFSF13/APRIL and TNFSF13B/TALL1/BAFF/BLYS that binds both ligands with similar high affinity. Mediates calcineurin-dependent activation of NF-AT, as well as activation of NF-kappa-B and AP-1. Involved in the stimulation of B- and T-cell function and the regulation of humoral immunity.
Subcellular Location	Membrane; Single-pass type III membrane protein.
Database References	HGNC: 18153 OMIM: 240500 KEGG: hsa:23495 STRING: 9606.ENSP00000261652 UniGene: Hs.158341
Associated Diseases	Immunodeficiency, common variable, 2 (CVID2); Immunoglobulin A deficiency 2 (IGAD2)
Tissue Specificity	Highly expressed in spleen, thymus, small intestine and peripheral blood leukocytes. Expressed in resting B-cells and activated T-cells, but not in resting T-cells.

Gene Functions References

Expression patterns of BAFF and its receptor TACI differ according to lupus nephritis class. PMID: 29087261
p.G76S gain-of-function mutation on the TNFRSF13B gene is responsible for familial or sporadic immune thrombocytopenia. PMID: 28834165
BAFF-induced processing of BAFFR regulates BAFF-mediated B cell responses in a TACI-dependent manner. PMID: 28249164
results suggest that TACI A181E heterozygosity results in TACI haploinsufficiency with increased susceptibility to pneumococcal infection PMID: 27609654
genetic polymorphism is associated with hypogammaglobulinemia and systemic lupus erythematosis in a family with common variable immunodeficiency disorder PMID: 26623716
11% of common variable immunodeficiency patients and 13% of antibody deficiency syndromes patients carried at least one mutated TNFRSF13B allele. PMID: 27123465
serum levels not associated with disease activity in MPO-ANCA-associated renal vasculitis PMID: 25567522
In this review, we aim at giving an insight into the genetics underlying the CVID and particularly at outlining the role of TACI and its relative contribution to the development of CVID-like phenotypes in human. PMID: 26096648
C104R mutation was associated with common variable immunodeficiency and IgG subclass deficiency. PMID: 26727773
TNFRSF13B hemizygosity does not recapitulate autoimmune features of common variable immune deficiency -associated C104R and A181E TNFRSF13B mutations, which likely encode dominant negative products, but instead reveals selective TACI haploinsufficiency at later stages of B-cell development. PMID: 26100089
Common variable immune deficiency patients with heterozygous mutations in TACI alleles increase susceptibility to autoimmune diseases. PMID: 25866827
The study demonstrated that there is a remarkable interindividual variability of TACI expression in chronic lymphocytic leukemia, although the majority of patients display low to undetectable TACI. PMID: 25950010
Variants of TNFRSF13B were associated with common variable immunodeficiency. PMID: 26122175
only Transmembrane Activator and CAML Interactor (TACI) correlates with the MMC's capability to ligate BAFF. Additionally, the level of expression of TACI correlates with the level of the MMC's BM dependency PMID: 25723853
Data show significant differences in expression of tumour necrosis factor family (BAFF) receptors BAFF-R, BCMA and TACI in patients with and without anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies. PMID: 25301447
Although the transcriptional controls for alternative splicing of TACI isoforms remain unknown, differential signals via isoforms may control plasma-cell generation. PMID: 25631768
In conclusion, we confirmed the prognostic significance of soluble BLyS levels with regard to TFT in CLL patients, and, more importantly, we showed for the first time that sTACI is a powerful prognostic marker, related to parameters of disease activity PMID: 25162001
The released sTACI is an immunoregulator that shares decoy functions with atacicept. It reflects systemic and compartmentalized B cell accumulation and activation. PMID: 25505277
genetic polymorphism is associated with lung function in Hutterites, who are a founder population of European descent in North America PMID: 23932459
TNFRSF13B/TACI defects alone do not result in CVID but may be also found frequently in distinct clinical phenotypes, including benign lymphoproliferation and IgG subclass deficiencies. PMID: 23956760
TACI mutations enables autoimmune complications in common variable immune deficiency . PMID: 24051380
Intracellular and extracellular TACI expression was defective for B cells of all subjects with mutations. PMID: 23237420
A significant association of TNFRSF13B gene mutations was observed in common variable immunodeficiency patients. PMID: 22884984
Naturally occurring mutation affecting the MyD88-binding site of TNFRSF13B impairs triggering of class switch recombination. PMID: 23225259
Segregation analysis of a kindred shows that inheriting single or double copy of the Cys104Arg mutation does not necessarily consign an individual to common variable immunodeficiency (CVID). PMID: 22983507
Two pediatric Italian male siblings were affected with hypogammaglobulinemia and recurrent respiratory and gastrointestinal infections in association with a novel compound heterozygous I87N/C104R TACI mutation. PMID: 22627058
Three SNPs located in TNFRSF13B on 17p11.2 or nearby were significantly associated with IgG level. PMID: 22673310
Data suggest a different impact of TACI mutations, from hypogammaglobulinemia in children to autoimmune disease in adulthood. PMID: 22697072
the identification of two novel mutations in TNFRSF13B, including one, S231R, affecting the highly conserved THC domain PMID: 22076597
We conclude that mutations in TACI are the contributing factors for asthma symptoms in Swedish children, although the mechanisms still remain elusive. PMID: 21850030
Our data provide further evidence that TNFRSF13B/TACI alterations are not causative of common variable immunodeficiency PMID: 21547394
Signals from TLR9, TACI, and CD40 are integrated to promote B-cell activation and differentiation. PMID: 21741080
primary leukemia B-cell precursors aberrantly express receptors of the BAFF-system, BAFF-R, BCMA, and TACI PMID: 21687682
We have examined the function of TACI coding variants that have been described in patients with common variable immunodeficiency PMID: 21419480
In patients with Smith-Magenis syndrome with only 1 TACI allele, we found decreased B-cell expression of TACI, reduced binding of a proliferation-inducing ligand, and decreased TACI-induced expression of activation-induced cytidine deaminase mRNA. PMID: 21514638
mutations result in impaired B cell response through haploinsufficiency PMID: 20889194
TACI expression on CD19+ B cells was up-regulated in patients with lupus nephritis PMID: 20974656
MyD88 controls a B cell-intrinsic, TIR-independent, TACI-dependent pathway for immunoglobulin diversification PMID: 20676093
the TNFRSF13B A181E mutation is associated with a very heterogeneous clinical presentation along with variability in B-cell numbers and amount of TACI protein on memory B cells in Common Variable ImmunoDeficiency PMID: 20156508
novel mutations identified in this study support the notion of a crucial role for TACI in B cell differentiation PMID: 19629655
Expression of BCMA, TACI, and BAFF-R by multiple myeloma cells support cell growth and survival. PMID: 14512299
TACI(hi) myeloma cells displayed a mature plasma cell gene signature, indicating dependence on the BM environment. In contrast, the TACI(lo) group had a gene signature of plasmablasts, suggesting an attenuated dependence on the BM environment PMID: 15827134
4 of 19 unrelated individuals with common variable immunodeficiency and 1 of 16 individuals with IgA deficiency had a missense mutation in one allele of TNFRSF13B PMID: 16007086
identified homozygous and heterozygous mutations in TNFRSF13B, encoding TACI, in 13 individuals with common variable immunodeficiency PMID: 16007087
Review. Short-lived antibody forming cell populations and their proliferating progenitors express a TACI-predominant signature. PMID: 16919470
The TACI inhibited HRS cell accumulation in vitro and might attenuate HL expansion in vivo. PMID: 16960154
simultaneous binding of TACI and HSPG on B cells with APRIL is crucial for IgA production PMID: 17119122
TACI-specific signaling inhibits both B cell activating factor of the TNF family receptor (BAFF-R) and CD40-enhanced antibody production from peripheral blood B cells in vitro, although TACI-specific signaling directly induces mild B cell apoptosis. PMID: 17154264
This review defines the exact contribution of TACI receptor stimulation by specific triggers in vitro, enabling us to better understand the complex, context-dependent responses initiated by TACI in vivo. PMID: 17171762
Role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency. PMID: 17392797

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.